Clinical Trial Detail

NCT ID NCT02562755
Title Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors SillaJen, Inc.
Indications

hepatocellular carcinoma

Therapies

JX-594

Sorafenib

Age Groups: adult

No variant requirements are available.